-+ 0.00%
-+ 0.00%
-+ 0.00%

Deutsche Bank Maintains Buy on Axsome Therapeutics, Lowers Price Target to $267

Benzinga·09/29/2026 14:27:02
Deutsche Bank analyst David Hoang maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $280 to $267.